Addendum
Resmetirom (metabolic dysfunction-associated steatohepatitis) – Addendum to Project A25-117
Report documents
-
Addendum
Resmetirom (metabolic dysfunction-associated steatohepatitis) – Addendum to Project A25-117
Dossier assessment
Indication:
Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3)
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
05-03-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-08
- Commission
- Commission awarded on 27.01.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-08_en
Connected Projects
-
Dossier assessment
Resmetirom (metabolic dysfunction-associated steatohepatitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed